Expression of SGLT1 and SGLT2 in Breast Cancer and Potential Anticancer Effects of SGLT1 Inhibitors

被引：0
|
作者：
Tsunokake, Satoko [1 ]
Iwabichi, Erina [2 ]
Miki, Yasuhiro [3 ]
Kanai, Ayako [4 ]
Onodera, Yoshiaki [3 ]
Ishida, Takanori [1 ]
Sasano, Hironobu [3 ]
Suzuki, Takashi [2 ,3 ,5 ]
机构：
[1] Tohoku Univ, Dept Breast & Endocrine Surg Oncol, Sendai, Miyagi, Japan
[2] Tohoku Univ, Dept Pathol & Histotechnol, Sendai, Miyagi, Japan
[3] Tohoku Univ, Dept Anat Pathol, Sendai, Miyagi, Japan
[4] Hachinohe Municipal Hosp, Dept Breast Surg, Hachinohe, Aomori, Japan
[5] Tohoku Univ Hosp, Dept Pathol, Sendai, Miyagi, Japan
来源：
CANCER SCIENCE | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-3266
引用
收藏
页码：1939 / 1939
页数：1
相关论文
共 50 条
  • [41] Adrenal SGLT1 or SGLT2 as predictors of atherosclerosis under chronic stress based on a computer algorithm
    Li, Jianyi
    Meng, Lingbing
    Wu, Dishan
    Xu, Hongxuan
    Hu, Xing
    Hu, Gaifeng
    Chen, Yuhui
    Xu, Jiapei
    Gong, Tao
    Liu, Deping
    PEERJ, 2023, 11
  • [42] Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?
    Pitt, Bertram
    Bhatt, Deepak L.
    Metra, Marco
    EUROPEAN HEART JOURNAL, 2022, 43 (45) : 4754 - 4757
  • [43] Development of a cell-based nonradioactive glucose uptake assay system for SGLT1 and SGLT2
    Kanwal, Abhinav
    Singh, Shailendra Pratap
    Grover, Paramjit
    Banerjee, Sanjay Kumar
    ANALYTICAL BIOCHEMISTRY, 2012, 429 (01) : 70 - 75
  • [44] SGLT1 inhibition: Pros and cons
    Tsimihodimos, Vasilis
    Filippas-Ntekouan, Sebastien
    Elisaf, Moses
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 838 : 153 - 156
  • [45] Synthesis and biological evaluation of benzocyclobutane-C-glycosides as potent and orally active SGLT1/SGLT2 dual inhibitors
    Kuo, Gee-Hong
    Gaul, Micheal D.
    Liang, Yin
    Xu, June Z.
    Du, Fuyong
    Hornby, Pamela
    Xu, Guozhang
    Qi, Jenson
    Wallace, Nathaniel
    Lee, Seunghun
    Grant, Eugene
    Murray, William V.
    Demarest, Keith
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (07) : 1182 - 1187
  • [46] Comparison of SGLT1, SGLT2, and Dual Inhibitor Biological Activity in Treating Type 2 Diabetes Mellitus
    Azizogli, Abdul-Rahman
    Vitti, Michael R.
    Mishra, Richa
    Osorno, Laura
    Heffernan, Corey
    Kumar, Vivek A.
    ADVANCED THERAPEUTICS, 2023, 6 (12)
  • [47] SGLT1 in Pancreatic a Cells Regulates Glucagon Secretion in Mice, Possibly Explaining the Distinct Effects of SGLT2 Inhibitors on Plasma Glucagon Levels
    Suga, Takayoshi
    Kikuchi, Osamu
    Kobayashi, Masaki
    Matsui, Sho
    Hashimoto, Hiromi H.
    Sasaki, Tsutomu
    Kakizaki, Satoru
    Yamada, Masanobu
    Kitamura, Tadahiro
    DIABETES, 2018, 67
  • [48] SGLT1: A Potential Drug Target for Cardiovascular Disease
    Zhao, Mengnan
    Li, Na
    Zhou, Hong
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2023, 17 : 2011 - 2023
  • [49] SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels
    Suga, Takayoshi
    Kikuchi, Osamu
    Kobayashi, Masaki
    Matsui, Sho
    Yokota-Hashimoto, Hiromi
    Wada, Eri
    Kohno, Daisuke
    Sasaki, Tsutomu
    Takeuchi, Kazusane
    Kakizaki, Satoru
    Yamada, Masanobu
    Kitamura, Tadahiro
    MOLECULAR METABOLISM, 2019, 19 : 1 - 12
  • [50] Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors
    Yakovleva, Tatiana
    Sokolov, Victor
    Chu, Lulu
    Tang, Weifeng
    Greasley, Peter J.
    Sjogren, Helena Peilot
    Johansson, Susanne
    Peskov, Kirill
    Helmlinger, Gabriel
    Boulton, David W.
    Penland, Robert C.
    DIABETES OBESITY & METABOLISM, 2019, 21 (12): : 2684 - 2693
12345